Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Stacey M. Fernandes(Dana-Farber Cancer Institute), Laura Z. Rassenti(University of California San Diego), Jon Arnason(Beth Israel Deaconess Medical Center), Elizabeth A. Morgan(Brigham and Women's Hospital), Joshua Fein(Dana-Farber Cancer Institute), Thomas J. Kipps(University of California San Diego), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Haesook T. Kim(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Tiago R. Matos(Sanofi (Netherlands)), David C. Fisher(Dana-Farber Cancer Institute), John Hanna(Dana-Farber Cancer Institute), Jeremy S. Abramson(Massachusetts General Hospital), Siddha Kasar(AVEO Oncology (United States)), Jerome Ritz(Dana-Farber Cancer Institute)
Cited by 289
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k